Cell-autonomous and non-cell-autonomous mechanisms of HGF/MET-driven resistance to targeted therapies: From basic research to a clinical perspective

Cancer Discovery

Volumn 3, Issue 9, 2013, Pages 978-992

  Corso, Simona ^a   Giordano, Silvia ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 208; B RAF KINASE; CABOZANTINIB; CETUXIMAB; CRIZOTINIB; EMD 1204831; EMD 1214063; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FICLATUZUMAB; FORETINIB; GEFITINIB; GOLVATINIB; INCB28060; K RAS PROTEIN; LAPATINIB; LY 2875358; MGCD 265; MITOGEN ACTIVATED PROTEIN KINASE; ONARTUZUMAB; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAC1 PROTEIN; RAS PROTEIN; RILOTUMUMAB; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; STAT3 PROTEIN; SUNITINIB; TAK 701; TIVANTINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR;

BRAIN CANCER; BREAST CANCER; BREAST METASTASIS; CELL AUTONOMOUS MECHANISM; CELL FUNCTION; COLON CANCER; COLORECTAL CANCER; GENE ACTIVATION; GENE AMPLIFICATION; GENE MUTATION; GLIOBLASTOMA; GLIOMA; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HUMAN; KIDNEY CANCER; LARGE CELL LYMPHOMA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MELANOMA; MESOTHELIOMA; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; NON CELL AUTONOMOUS MECHANISM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; STOMACH CANCER; THERAPY RESISTANCE; THYROID CANCER; TRIPLE NEGATIVE BREAST CANCER;

APOPTOSIS; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; HEPATOCYTE GROWTH FACTOR; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET;

EID: 84885234293     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-13-0040     Document Type: Review

References (76)

1. Gschwind A, Fischer OM, Ullrich A The discovery of receptor tyrosine kinases: targets for cancer therapy Nat Rev Cancer 2004; 4: 361-70
2. Weinstein IB, Joe AK Mechanisms of disease: Oncogene addictiona rationale for molecular targeting in cancer therapy Nat Clin Pract Oncol 2006; 3: 448-57
3. Giordano S, Ponzetto C, Di Renzo MF, Cooper CS, Comoglio PM Tyrosine kinase receptor indistinguishable from the c-met protein Nature 1989; 339: 155-6
4. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, et al. Identifi cation of the hepatocyte growth factor receptor as the c-met proto-oncogene product Science 1991; 251: 802-4
5. Trusolino L, Bertotti A, Comoglio PM MET signalling: principles and functions in development, organ regeneration and cancer Nat Rev Mol Cell Biol 2010; 11: 834-48
6. Misra S, Heldin P, Hascall VC, Karamanos NK, Skandalis SS, Markwald RR, et al. Hyaluronan-CD44 interactions as potential targets for cancer therapy FEBS J 2011; 278: 1429-43
7. Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, Ponta H CD44 is required for two consecutive steps in HGF/c-Met signaling Genes Dev 2002; 16: 3074-86
8. Orian-Rousseau V, Morrison H, Matzke A, Kastilan T, Pace G, Herrlich P, et al. Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin Mol Biol Cell 2007; 18: 76-83
9. Trusolino L, Bertotti A, Comoglio PM A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth Cell 2001; 107: 643-54
10. Giordano S, Corso S, Conrotto P, Artigiani S, Gilestro G, Barberis D, et al. The semaphorin 4D receptor controls invasive growth by coupling with Met Nat Cell Biol 2002; 4: 720-4
11. Wang X, DeFrances MC, Dai Y, Pediaditakis P, Johnson C, Bell A, et al. A mechanism of cell survival: sequestration of Fas by the HGF receptor Met Mol Cell 2002; 9: 411-21
12. Jo M, Stolz DB, Esplen JE, Dorko K, Michalopoulos GK, Strom SC Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells J Biol Chem 2000; 275: 8806-11
13. Bergström JD, Westermark B, Heldin NE Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells Exp Cell Res 2000; 259: 293-9
14. Fischer OM, Giordano S, Comoglio PM, Ullrich A Reactive oxygen species mediate Met receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells J Biol Chem 2004; 279: 28970-8
15. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF Met, metastasis, motility and more Nat Rev Mol Cell Biol 2003; 4: 915-25
16. McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, et al. Identifi cation of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profi ling Proc Natl Acad Sci U S A 2007; 104: 19936-41
17. Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H, et al. Amplifi cation of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752 Proc Natl Acad Sci U S A 2006; 103: 2316-21
18. Corso S, Migliore C, Ghiso E, De Rosa G, Comoglio PM, Giordano S Silencing the MET oncogene leads to regression of experimental tumors and metastases Oncogene 2008; 27: 684-93
19. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene Cancer Cell 2003; 3: 347-61
20. Ivan M, Bond JA, Prat M, Comoglio PM, Wynford-Thomas D Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells Oncogene 1997; 14: 2417-23
21. Gambarotta G, Boccaccio C, Giordano S, AndǒM, Stella MC, Comoglio PM Ets up-regulates MET transcription. Oncogene 1996; 13: 1911-7
22. Hwang CI, Matoso A, Corney DC, Flesken-Nikitin A, Körner S, Wang W, et al. Wild-type p53 controls cell motility and invasion by dual regulation of MET expression Proc Natl Acad Sci U S A 2011; 108: 14240-5
23. Migliore C, Martin V, Leoni VP, Restivo A, Atzori L, Petrelli A, et al. MiR-1 downregulation cooperates with MACC1 in promoting MET overexpression in human colon cancer Clin Cancer Res 2012; 18: 737-47
24. Taulli R, Bersani F, Foglizzo V, Linari A, Vigna E, Ladanyi M, et al. The muscle-specifi c microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation J Clin Invest 2009; 119: 2366-78
25. Peters S, Adjei AA MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol 2012; 9: 314-26
26. Kentsis A, Reed C, Rice KL, Sanda T, Rodig SJ, Tholouli E, et al. Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia Nat Med 2012; 18: 1118-22
27. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas Nat Genet 1997; 16: 68-73
28. Schmidt L, Junker K, Nakaigawa N, Kinjerski T, Weirich G, Miller M, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas Oncogene 1999; 18: 2343-50
29. Michieli P, Basilico C, Pennacchietti S, Maffè A, Tamagnone L, Giordano S, et al. Mutant Met-mediated transformation is liganddependent and can be inhibited by HGF antagonists Oncogene 1999; 18: 5221-31
30. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplifi cation leads to gefi tinib resistance in lung cancer by activating ERBB3 signaling Science 2007; 316: 1039-43
31. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, et al. MET amplify cation occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefi tinib or erlotinib Proc Natl Acad Sci U S A 2007; 104: 20932-7
32. Arcila ME, Oxnard GR, Nafa K, Riely GJ, Solomon SB, Zakowski MF, et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay Clin Cancer Res 2011; 17: 1169-80.
33. Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers Clin Cancer Res 2013; 19: 2240-7
34. Miller CT, Lin L, Casper AM, Lim J, Thomas DG, Orringer MB, et al. Genomic amplifi cation of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma Oncogene 2006; 25: 409-18
35. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, et al. Preexistence and clonal selection of MET amplifi cation in EGFR mutant NSCLC Cancer Cell 2010; 17: 77-88
36. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 2001; 344: 783-92
37. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer N Engl J Med 2011; 365: 1273-83
38. Valabrega G, Montemurro F, Sarotto I, Petrelli A, Rubini P, Tacchetti C, et al. TGFalpha expression impairs Trastuzumab-induced HER2 downregulation Oncogene 2005; 24: 3002-10
39. Scaltriti M, Rojo F, Ocaña A, Anido J, Guzman M, Cortes J, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer J Natl Cancer Inst 2007; 99: 628-38
40. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, et al. A functional genetic approach identifi es the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer Cancer Cell 2007; 12: 395-402
41. Shattuck DL, Miller JK, Carraway KL, Sweeney C Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells Cancer Res 2008; 68: 1471-7
42. Minuti G, Cappuzzo F, Duchnowska R, Jassem J, Fabi A, O'Brien T, et al. Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer Br J Cancer 2012; 107: 793-9
43. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the effi cacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Lancet Oncol 2010; 11: 753-62
44. Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifi es HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer Cancer Discov 2011; 1:508-23
45. Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 2011; 3: 99ra86
46. Diaz LA, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers Nature 2012; 486: 537-40
47. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer Nature 2012; 486: 532-6
48. Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, et al. Amplifi cation of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer Cancer Discov 2013;3: 658-73
49. Jun HJ, Acquaviva J, Chi D, Lessard J, Zhu H, Woolfenden S, et al. Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme Oncogene 2012; 31: 3039-50
50. Go H, Jeon YK, Park HJ, Sung SW, Seo JW, Chung DH High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer J Thorac Oncol 2010; 5: 305-13
51. Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients J Clin Oncol 2009; 27: 1667-74
52. Tanaka A, Sueoka-Aragane N, Nakamura T, Takeda Y, Mitsuoka M, Yamasaki F, et al. Co-existence of positive MET FISH status with EGFR mutations signifi es poor prognosis in lung adenocarcinoma patients Lung Cancer 2012; 75: 89-94
53. Suda K, Murakami I, Katayama T, Tomizawa K, Osada H, Sekido Y, et al. Reciprocal and complementary role of MET amplifi cation and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res 2010; 16: 5489-98
54. Kerbel R, Folkman J Clinical translation of angiogenesis inhibitors Nat Rev Cancer 2002; 2: 727-39
55. Meads MB, Gatenby RA, Dalton WS Environment-mediated drug resistance: a major contributor to minimal residual disease Nat Rev Cancer 2009; 9: 665-74
56. Williams RT, den Besten W, Sherr CJ Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia Genes Dev 2007; 21: 2283-7
57. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012; 487: 505-9
58. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion Nature 2012; 487: 500-4
59. Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth J Cell Biol 1992; 119: 629-41
60. Zhang YW, Su Y, Volpert OV, Vande Woude GF Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation Proc Natl Acad Sci U S A 2003; 100: 12718-23
61. Harbinski F, Craig VJ, Sanghavi S, Jeffery D, Liu L, Sheppard KA, et al. Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth Cancer Discov 2012; 2: 948-59
62. Shojaei F, Lee JH, Simmons BH, Wong A, Esparza CO, Plumlee PA, et al. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors Cancer Res 2010; 70: 10090-100
63. Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, et al. Hepatocyte growth factor induces gefi tinib resistance of lungadenocarcinoma with epidermal growth factor receptor-activating mutations Cancer Res 2008; 68: 9479-87
64. Yano S, Yamada T, Takeuchi S, Tachibana K, Minami Y, Yatabe Y, et al.Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort J Thorac Oncol 2011; 6: 2011-7
65. Tanaka H, Kimura T, Kudoh S, Mitsuoka S, Watanabe T, Suzumura T, et al. Reaction of plasma hepatocyte growth factor levels in non-small cell lung cancer patients treated with EGFR-TKIs Int J Cancer 2011; 129: 1410-6
66. Yamada T, Takeuchi S, Kita K, Bando H, Nakamura T, Matsumoto K, et al. Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer J Thorac Oncol 2012; 7: 272-80
67. Yamada T, Takeuchi S, Nakade J, Kita K, Nakagawa T, Nanjo S, et al. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells Clin Cancer Res 2012; 18: 3592-602
68. Crinó L, Kim D, Riely GJ, Janne PA, Blackhall FH, Camidge D R, et al. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005 J Clin Oncol 29: 2011 (suppl; abstr 7514).
69. Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforow S, Zheng W, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors Cancer Res 2011; 71: 6051-60
70. Mueller KL, Madden JM, Zoratti GL, Kuperwasser C, List K, Boerner JL Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triplenegative breast cancers through paracrine activation of Met Breast Cancer Res 2012; 14: R104
71. Chen CT, Kim H, Liska D, Gao S, Christensen JG, Weiser MR MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells Mol Cancer Ther 2012; 11: 660-9
72. Liska D, Chen CT, Bachleitner-Hofmann T, Christensen JG, Weiser MR HGF rescues colorectal cancer cells from EGFR inhibition via MET activation Clin Cancer Res 2011; 17: 472-82
73. Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwall R, et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo Clin Cancer Res 2006; 12: 6144-52
74. Spigel D, Ervin T, Ramlau R, Daniel D, Goldschmidt J, Krzakowski M, et al. Randomized multicenter double-blind placebocontrolled phase ii study evaluating metmab, an antibody to met receptor, in combination witherlotinib, in patients with advanced non-smallcell lung cancer. Ann Oncol 2010;21 Suppl 8:viii1-viii12
75. Wang F, Flanagan J, Su N, Wang LC, Bui S, Nielson A, et al. RNAscope: a novel in situ RNA analysis platform for formalin-fi xed, paraffi n-embedded tissues J Mol Diagn 2012; 14: 22-9
76. Ikebuchi F, Oka K, Mizuno S, Fukuta K, Hayata D, Ohnishi H, et al. Dissociation of c-Met phosphotyrosine sites in human cells in response to mouse hepatocyte growth factor but not human hepatocyte growth factor: the possible roles of different amino acids in different species Cell Biochem Funct. 2012 Sep 20 [Epub ahead of print]